SB-269,970

SB-269,970

SB-269,970 is a drug and research chemical developed by GlaxoSmithKline used in scientific studies. It was previously believed to act as a selective 5-HT7 receptor antagonist (or possibly inverse agonist), but a subsequent discovery showed that it also potently blocks the α2-adrenergic receptor.[1][2][3] The new finding has raised significant concerns about studies using SB-269,970 as a specific serotonin receptor antagonist.[3]

SB-269,970 is used to study the 5-HT7 receptors which are thought to be involved in the function of several areas of the brain such as the hippocampus and thalamus,[4] and regulation of dopamine release in the ventral tegmental area.[5] Possible therapeutic uses for SB-269,970 and other 5-HT7 antagonists include the treatment of anxiety and depression,[6][7] and nootropic effects have also been noted in animal studies.[8][9]

References